Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Conditions
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
Interventions
KQB365, Cetuximab, KQB198
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Conditions
Migraine Headaches
Interventions
Sumatriptan and Naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greensboro, North Carolina
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
Conditions
Solid Tumor, Adult
Interventions
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
Drug
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Not listed Phase 3 Interventional Accepts healthy volunteers

Identigene STD Test Collection Kit Validation Study

NCT01471392
Conditions
Infection
Interventions
STD Diagnostic Kit (Identigene)
Device
Lead sponsor
Identigene
Industry
Eligibility
14 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Mellitus
Interventions
blood glucose measurement
Other
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Actinic Keratosis
Interventions
lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Melanoma
Interventions
EIK1001, Pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
14
States / cities
Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Pembrolizumab, Belzutifan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
4,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
113
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
Conditions
Advanced Solid Tumor
Interventions
YL217, Bevacizumab, 5-FU with leucovorin
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • New Haven, Connecticut + 9 more
Conditions
Breast Cancer
Interventions
CNF2024, CNF2024 + trastuzumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Tampa, Florida • New York, New York • Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

Decitabine and Talazoparib in Untreated AML and R/R AML

NCT02878785
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, talazoparib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670
Conditions
Hyperglycemia
Interventions
5% dextrose, Vitamin C, Simvastatin, Sevoflurane
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Myelofibrosis
Interventions
CK0804
Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Sacramento, California • New York, New York • The Bronx, New York + 1 more
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Salt Lake City, Utah
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RM1 Project 1 - tAN Naloxone

NCT05490134
Conditions
Analgesia
Interventions
Naloxone, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
ZD6474 (Vandetanib), Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

NCT03096444
Conditions
Pruritus
Interventions
Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream
Drug · Combination Product
Lead sponsor
Gil Yosipovitch
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more